Zynerba burned by second trial failure

The cannabinoid drugmaker disclosed its second clinical failure in as many weeks.

By Lisa LaMotta • Aug. 14, 2017

Prescribed Reading: Merger as a band-aid for biotech troubles

Multiple biotechs with ongoing problems discovered solutions this week by merging with privately held companies, which could offer a needed boost. 

By Lisa LaMotta • Aug. 11, 2017

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.

By BioPharma Dive staff

Heron's post-surgery painkiller swoops into Phase 3

On a mission to cut opioid use following surgery, Heron is launching two Phase 3 trials to further advance its non-opioid analgesic.

By Suzanne Elvidge • Aug. 11, 2017

Alnylam review turns up no clear answers on revusiran deaths

A higher number of patient deaths in the treatment arm of a Phase 3 study had led Alnylam last year to abandon revusiran, then its lead program. 

By Ned Pagliarulo • Aug. 10, 2017

Galapagos' new data is good, but how much weight does it carry?

At least one analyst notes that it may be too early to tell whether the company's lung drug can stack up against rival therapies.

By Jacob Bell • Aug. 10, 2017

Accelerate your database lock using Clean Patient Optics

Using the powerful data visualization tools in Clean Patient Optics, study teams can uncover patterns about the status of patient data external to the EDC system for early identification of potential study problems.

Aug. 8, 2017

Esperion hits a homer with new cholesterol data

Stock surged on news that patients taking a statin and a drug combination including its bempedoic acid had a 64% reduction in bad cholesterol levels.

By Jacob Bell • Aug. 8, 2017

Investors breathe life into FibroGen after positive lung data

Shares of the biotech skyrocketed on news its lung drug beat out a placebo in a mid-stage study. 

By Lisa LaMotta • Aug. 8, 2017

Zynerba shares up in smoke after trial failure

Shares in the biotech fell sharply after it announced negative topline results for its lead product in a clinical trial. 

By Lisa LaMotta • Aug. 7, 2017

MyoKardia seeks accelerated development for heart drug

Positive findings from a small study have prompted the biotech to seek a more aggressive clinical pathway for its genetic heart disease drug. 

By Suzanne Elvidge • Aug. 7, 2017

Lilly's turn to pain gathers momentum

Positive data for the drugmaker's other migraine drug lasmiditan adds another late-stage success to an emerging portfolio of new treatments for pain.

By Ned Pagliarulo • Aug. 7, 2017

Placebo response dulls otherwise shiny results for Gemphire drug

A higher than expected response in the control group of the cholesterol study pushed down shares, despite a positive outcome. 

By Jacob Bell • Aug. 7, 2017

Prescribed Reading: More portfolios reshuffled

Restructuring continued throughout the industry, as more companies attempt to cut costs or excess programs. Meanwhile, the FDA kept up its rapid pace of drug approvals.

By Lisa LaMotta • Aug. 4, 2017

So far, so good for Spark in hemophilia A

Three patients dosed with SPK-8011 have demonstrated improved Factor VIII levels and no serious adverse effects.

By Jacob Bell • Aug. 3, 2017

Cytokinetics inches forward with heart failure program

Amgen and the smaller biotech have been developing omecamtiv mercabil since 2006, pushing through a clinical setback and dimming commercial prospects for the class. 

By Ned Pagliarulo • Aug. 2, 2017

Theravance downplays mixed data in GI study

In a Phase 2 study, Theravance's velusetrag turned up statistically significant results for one dose, but failed in others. 

By Lisa LaMotta • Aug. 2, 2017

23andMe, Lundbeck unveil mega investigation of genetics' role in depression

Enrollment has already begun for the 25,000-person investigation.

By Jacob Bell • Aug. 2, 2017

Bristol-Myers, Clovis ink industry's latest PARP deal

The companies plan to investigate the combination of Opdivo and Rubraca as a treatment for various cancers.

By Jacob Bell • Aug. 1, 2017

Unfazed by competition, Allergan sees room at CGRP table

Allergan believes it can break into the emerging CGRP migraine market, even as it lags behind other drugmakers' rival products.

By Ned Pagliarulo • July 28, 2017

Prescribed Reading: Pharma marked by restructuring and failures

A week of earnings announcements emphasized changes in portfolios against the backdrop of a major pipeline failure. 

By Lisa LaMotta • July 28, 2017

Bristol shrugs off comparisons to MYSTIC

The big pharma was faced with an onslaught of questions regarding the potential of its own PD-1/CTLA4 combination after AstraZeneca's failure.

By Lisa LaMotta • July 28, 2017

Vertex set up for CF monopoly due to data, contracts

The rollout of further data for its triple combination cystic fibrosis treatments, as well as agreements with payers, could allow the biotech to wipe out competition.

By Lisa LaMotta • July 27, 2017

Quark wins in Phase 2, raising the stakes for RNAi

The company is trying to best Alnylam in being the first to secure FDA approval for an RNAi therapy.

By Jacob Bell • July 27, 2017

MYSTIC flop a major blow to AstraZeneca's I/O hopes

Much-anticipated results from the Phase 3 lung cancer study showed a combination of Imfinzi and tremelimumab failed to deliver a progression-free survival benefit.

By Ned Pagliarulo • July 27, 2017

Tetraphase gains on strong antibiotic results

Shares of the biotech jumped on positive late-stage results, ahead of regulatory filings for the company's antibiotic.

By Lisa LaMotta • July 26, 2017